Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in Hospitalized COVID-19 Pneumonia Patients
2020-002753-22Phase 2Completed
- Sponsor
- Ferrer
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of favipiravir in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Ferrer. Primary endpoint: Time to clinical improvement. Started Jul 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002753-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002753-22.